ONC:NASDAQ
BeOne Medicines AG
367,00 USD
arrow_upward
+1,70%(+6,15) 1D
362,28 USD
arrow_downward
-1,29% (-4,72)todayPre-market
Closed: 28-сен., 16:00:00 GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ONC...
Open
360,42 USD
High
368,05 USD
Low
358,00 USD
Mkt. cap
43,80 млд
Avg. vol.
378,99 миң
Volume
0,00
52-wk high
385,22 USD
52-wk low
253,95 USD
Beta
0,51
Shares outstanding
109,79 млн
No. of employees
12 миң
Open
360,42 USD
High
368,05 USD
Low
358,00 USD
Mkt. cap
43,80 млд
Avg. vol.
378,99 миң
Volume
0,00
52-wk high
385,22 USD
52-wk low
253,95 USD
Beta
0,51
Shares outstanding
109,79 млн
No. of employees
12 миң
News stories
From web sources and news partners
TipRanks
·
15 саат мурун
BeOne Medicines Advances BGB-58067 Tablet Study, Sharpening Early-Stage Investor Focus
www.dars.gov.et
·
2 ай мурун
ONC Q1 2026 Earnings: Massive EPS Beat with 110% Surprise Amid Stock Decline - Estimate Accuracy
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12 миң
Founded2010-ж., 28-окт.
Headquarters-
Sector-
Websitebeonemedicines.com